China-developed COVID-19 vaccine to enter late-stage trial in Uzbekistan

2020-11-14 18:21:30Xinhua Editor : Li Yan ECNS App Download
Special: Battle Against Novel Coronavirus

The Uzbek government has recently told media that the country will carry out a phase-3 trial of a China-developed vaccine for COVID-19, which makes the vaccine China's fifth candidate to enter late-stage human tests overseas.

The ministry has announced that 5,000 Uzbek volunteers aged between 18 and 59 will attend the third phase of the pilot process, which will continue for a year.

Developed by China's Anhui Zhifei Longcom Biopharmaceutical, the trial vaccine has been transported to Uzbekistan along with several Chinese specialists who will work on the monitoring of participants and training of Uzbek doctors.

Uzbekistan has so far confirmed 69,830 COVID-19 cases and 594 deaths, with 67,092 patients recovered.


Most popular in 24h

MoreTop news


Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2020 All rights reserved.
Reproduction in whole or in part without permission is prohibited.